Adverse reactions to antiretroviral drugs in patients receiving therapy in a Federal teaching hospital Southwest Nigeria

Main Article Content

Sikiru Usman
Ibrahim Oreagba
Olalekan Agede
Awodele Olufunsho
Chioma Ejekam
Akinwunmi Akinyede
Titilope Adeyemo
Oluranti Opanuga
Sunday Olayemi
Sulaimon Akanmu

Abstract

Background: Antiretroviral drugs have proven efficacy in reducing viral load to undetectable plasma levels. Although, adverse reactions to antiretroviral drugs may cause death, prolongation of hospitalization, nonadherence and treatment failure in HIV infected persons; they are not fully documented in Nigeria. It is therefore necessary to evaluate adverse reactions of patients to antiretroviral drugs in Nigeria.


Objectives: This study aimed to document the adverse reactions to antiretroviral drugs (ARVs) in HIV-positive patients, assess their severity causality and identify the risk factors for the development of the ADRs.


Methods: With the aid of data capture form and interview, information about ADR was obtained prospectively from 51 new patients eligible to commence ARV for a period of 3 months. The retrospective arm made use of information extracted from the case notes of 137 ARV-experienced patients selected using a web-based random method from June 2009 – July 2010).


Results: Dizziness (17.40%) was the most frequently reported adverse event in both arms of the study followed by body weakness (11.85%), anemia (11.11%), rash (9.63%), pruritus (9.63%), nausea and vomiting (7.41%) and fatigue (7.41%). Majority of suspected ADRs were mild (76.5%) while only few were severe (3.9%). Female + 3 gender (p=0.0010), CD4 cells count below 200 cells/mm (p=0.0005) and antiretroviral drug combination of Zidovudine + lamivudine + nevirapine (p=0.0099) were significantly associated with the development of ADRs to ARVs.


Conclusion: The most common adverse event to antiretroviral drugs in this study was dizziness followed by body weakness, anaemia, skin rash, body itching, lipodystrophy, nausea and vomiting. Most of the ADRs were mild and their development was significantly associated with female gender, CD4+ cells count below 200 cells/mm3 and antiretroviral drug combination of Zidovudine + lamivudine + nevirapine.

Downloads

Download data is not yet available.

Article Details

How to Cite
Usman, S., Oreagba, I., Agede, O., Olufunsho, A., Ejekam, C., Akinyede, A., Adeyemo, T., Opanuga, O., Olayemi, S., & Akanmu, S. (2023). Adverse reactions to antiretroviral drugs in patients receiving therapy in a Federal teaching hospital Southwest Nigeria. West African Journal of Pharmacy, 25(2), 21-30. https://doi.org/10.60787/wapcp-25-2-23
Section
Articles
Author Biographies

Ibrahim Oreagba, National Pharmacovigilance Centre, National Agency for Food and Drug Administration and Control, Abuja, Nigeria

Department of Pharmacology, Therapeutics and Toxicology, College of Medicine, University of Lagos, P.M.B. 12003, Idiaraba, Lagos, Nigeria 

Titilope Adeyemo, AIDS Prevention Initiative in Nigeria (APIN) Clinic, Lagos University Teaching Hospital, Idiaraba, Lagos, Nigeria.

Department of Hematology and Blood Transfusion, College of Medicine, University of Lagos, P.M.B. 12003, Idiaraba, Lagos, Nigeria 

Sulaimon Akanmu, Department of Hematology and Blood Transfusion, College of Medicine, University of Lagos, P.M.B. 12003, Idiaraba, Lagos, Nigeria 

AIDS Prevention Initiative in Nigeria (APIN) Clinic, Lagos University Teaching Hospital, Idiaraba, Lagos, Nigeria

References

UNAIDS (2012). Data on the size of the epidemic: Prevalence of HIV among adults aged 15 to 49. Available at: http://apps.who.int/gho/data/Accessed 9 January 2013

WHO Progress report (2010). Global HIV/AIDS response; Available at: www.who.int/gho/data/22100xcc Accessed 8August 2012.

World Health Organization (2006). Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. Geneva: World Health Organization; Available at: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. Accessed 13 January 2012.

d'Arminion MA, Lepri AC, Rezza G, Pezzoti P, Antinori A, Phillips AN, et al (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients: Italian cohort of antiretroviral Naive patients. AIDS 14:499-507.

Lucas GM, Chaisson RE, Moore RD (2010). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-7.

Pollard RB, Robinson P, Dransfield K (1998). Safety profile of treatment of human immunodeficiency virus infection. Clin Ther 20: 1071-1092.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing

antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35: 182-189

Blanch J, Martinez E, Rousaud A (2001). Preliminary data of a prospective study on neuropsychiatric side effects after initiation of

efavirenz. J Acquir Immune Defic Syndr 27: 336-343

De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G (2002). Periconceptional exposure to efavirenz and neural tube defects. Arch InternMed 2002; 162: 355

Van Leth F, Phanuphak P, Ruxrungtham K, and 2NN Study Team (2004) . Comparison of firstline antiretroviral therapy with regimens

including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363:

-1263

Temesgen Z. HIV infection. In: Habermann TJ (2006). Mayo Clinic Internal Medicine Review 7th ed. Rochester, Minn: Mayo Clinic Scientific Press;465-491.

Cooley LA, Lewin SR (2003). HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol. 26: 121-132.

Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O and Hamelmann C. (2012). Adverse drug reactions to antiretroviral therapy (ARVs):

incidence, type and risk factors in Nigeria. BMC Clinical Pharmacology 28 ; 2 ( 1 ) : 14 . doi:10.1186/1472-6904-12-14

Kenneth A. Agu and Azuka C. Oparah (2013). Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 4(2): 117–124. doi: 10.4103/2229-3485.111784

Bartlett, J. E., II; Kotrlik, J. W.; Higgins, C (2001). "Organizational research: Determining appropriate sample size for survey research".

Information Technology, Learning, and Performance Journal 19 (1): 43–50.

Koduri PR, Parekh S (2003). Zidovudine-related anemia with recticulocytosis. Ann Hematol 82 (3): 184–185.

Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F (2007). Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 8(8): 483–490.

Fagot J P, Mocke n haupt M , Bouwes - Bavinck JN (2001). Nevirapine and the risk of Stevens Johnson syndrome or toxic epidermal

necrolysis. AIDS 15(14): 1843–1848.

U.S. Department of Health and Human Services (2012). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >> 

Similar Articles

You may also start an advanced similarity search for this article.